Cladribine monotherapy in a patient with coexisting Crohn’s disease and multiple sclerosis

Patients with coexisting Crohn’s disease (CD) and multiple sclerosis (MS) present a complex therapeutic challenge, especially when standard dual-purpose therapies such as anti-integrins or S1P receptor modulators are contraindicated. We report the first case of a 22-year-old male successfully managed with cladribine monotherapy, achieving sustained clinical remission of both CD and MS over a four-year follow-up. Cladribine is an immune reconstitution therapy targeting T and B lymphocytes, with additional immunomodulatory effects that may benefit both conditions. This case highlights the potential of cladribine as a reliable treatment option in selected patients with concomitant CD and MS, warranting further investigation.